patents.google.com

SG11202112412QA - Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors - Google Patents

  • ️Thu Dec 30 2021
Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Info

Publication number
SG11202112412QA
SG11202112412QA SG11202112412QA SG11202112412QA SG11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA Authority
SG
Singapore
Prior art keywords
egfr
tyrosine kinase
kinase inhibitors
combination therapies
bispecific anti
Prior art date
2019-05-14
Application number
SG11202112412QA
Inventor
Sylvie Laquerre
Matthew Lorenzi
Sheri Moores
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2019-05-14
Filing date
2020-05-14
Publication date
2021-12-30
2020-05-14 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
2020-05-14 Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
2021-12-30 Publication of SG11202112412QA publication Critical patent/SG11202112412QA/en

Links

  • 238000002648 combination therapy Methods 0.000 title 1
  • 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 title 1

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202112412QA 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors SG11202112412QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11202112412QA true SG11202112412QA (en) 2021-12-30

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112412QA SG11202112412QA (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Country Status (12)

Country Link
EP (1) EP3968985A4 (en)
JP (1) JP2022531980A (en)
KR (1) KR20220010731A (en)
CN (1) CN113840601A (en)
AU (1) AU2020275272A1 (en)
BR (1) BR112021022828A2 (en)
CA (1) CA3140360A1 (en)
EA (1) EA202193117A1 (en)
IL (1) IL287962A (en)
MA (1) MA55978A (en)
MX (1) MX2021013955A (en)
SG (1) SG11202112412QA (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AR070861A1 (en) * 2008-03-06 2010-05-12 Genentech Inc USE OF COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS
RS65965B1 (en) * 2010-04-20 2024-10-31 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN104955838B (en) * 2012-11-21 2021-02-02 詹森生物科技公司 Bispecific EGFR/c-Met antibodies
AR111469A1 (en) * 2017-04-21 2019-07-17 Yuhan Corp COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME

Also Published As

Publication number Publication date
MX2021013955A (en) 2022-03-11
CN113840601A (en) 2021-12-24
EP3968985A4 (en) 2023-07-26
KR20220010731A (en) 2022-01-26
CA3140360A1 (en) 2020-11-19
IL287962A (en) 2022-01-01
AU2020275272A1 (en) 2021-12-02
MA55978A (en) 2022-03-23
EP3968985A1 (en) 2022-03-23
BR112021022828A2 (en) 2022-04-12
JP2022531980A (en) 2022-07-12
EA202193117A1 (en) 2022-02-11

Similar Documents

Publication Publication Date Title
PH12021552798A1 (en) 2022-09-19 Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
IL285718A (en) 2021-10-31 Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
EP3889174A4 (en) 2024-07-24 Homodimer-type bispecific antibody against her2 and cd3 and use thereof
EP3399968A4 (en) 2019-07-24 Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
PH12018500710A1 (en) 2018-10-15 Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MX2022014762A (en) 2023-01-11 Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use.
IL279251A (en) 2021-01-31 Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
MX358728B (en) 2018-09-03 Humanized pan-her antibody compositions.
TN2017000470A1 (en) 2019-04-12 Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2017004311A (en) 2017-12-07 Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
IL276303A (en) 2020-09-30 Methods for treating cancer with anti-pd-1 antibodies
ZA202006247B (en) 2021-09-29 Bispecific egfr/cd16 antigen-binding protein
TN2019000161A1 (en) 2020-10-05 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
IL255138A0 (en) 2017-12-31 Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
EP3328426B8 (en) 2021-06-02 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)
IL279325A (en) 2021-01-31 Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
IL287962A (en) 2022-01-01 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
IL255582A (en) 2018-01-31 Methods and preparations for inhibiting the egf/egfr pathway in combination with tyrosine kinase inhibitors
IL308225A (en) 2024-01-01 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors